๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Metastatic/Locally Advanced Non-Small-Cell Lung Cancer

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites๐Ÿ“ Santa Rosa๐Ÿ“ Hartford๐Ÿ“ Washington D.C. VM Oncology, LLC ยท Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites๐Ÿ“ Villejuif๐Ÿ“ Bordeaux๐Ÿ“ Dijon Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: ASP3082 Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site๐Ÿ“ Shanghai Akeso ยท Tests: Ivonescimab, docetaxel, Placebo, docetaxel A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites๐Ÿ“ Washington D.C.๐Ÿ“ Athens๐Ÿ“ Lexington Bristol-Myers Squibb ยท Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites๐Ÿ“ Aurora๐Ÿ“ Lake Mary๐Ÿ“ Lebanon 7 Hills Pharma, LLC ยท Tests: Alintegimod, Ipilimumab, Nivolumab Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites๐Ÿ“ Sacramento๐Ÿ“ Tampa๐Ÿ“ Tampa National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724n/a2 sites๐Ÿ“ Sankt Pรถlten๐Ÿ“ Frankfurt am Main Institut fรผr Klinische Krebsforschung IKF GmbH at Krankenhaโ€ฆ A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M09D1 Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer NCT07288632n/a1 site๐Ÿ“ Perugia University Of Perugia FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations NCT06669117Phase 1, Phase 219 sites๐Ÿ“ Washington D.C.๐Ÿ“ Canton๐Ÿ“ Nashville Pierre Fabre Medicament ยท Tests: VERT-002 A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Guangzhou Henan Genuine Biotech Co., Ltd. ยท Tests: Dositinib mesylate tablets A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3301 sites๐Ÿ“ Mobile๐Ÿ“ Chandler๐Ÿ“ Phoenix AstraZeneca ยท Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites๐Ÿ“ Springdale๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites๐Ÿ“ Tucson๐Ÿ“ Hot Springs๐Ÿ“ Little Rock AstraZeneca ยท Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul Yuhan Corporation ยท Tests: YH32364 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790Phase 3204 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ La Jolla Bristol-Myers Squibb ยท Tests: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728Phase 32 sites๐Ÿ“ Changsha๐Ÿ“ Shanghai TYK Medicines, Inc ยท Tests: TY-9591, placebo Osimertinib, Osimertinib, placebo TY-9591 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities NCT07308106Phase 21 site๐Ÿ“ Shanghai Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB571 for injection Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126Phase 3246 sites๐Ÿ“ Anchorage๐Ÿ“ Fountain Valley๐Ÿ“ Los Angeles Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer NCT06955988Phase 11 site๐Ÿ“ Shanghai Allist Pharmaceuticals, Inc. ยท Tests: AST2303 Tablets(ABK3376 Tablets) ๏ผŒ25mg, AST2303 Tablets(ABK3376 Tablets) ๏ผŒ50mg, AST2303 Tablets(ABK3376 Tablets) ๏ผŒ75mg,โ€ฆ ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI NCT06388031Phase 21 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Immune checkpoint inhibitor Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites๐Ÿ“ Fullerton๐Ÿ“ Los Angeles๐Ÿ“ Orange ArriVent BioPharma, Inc. ยท Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site๐Ÿ“ Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. ยท Tests: Drug: IBI3028 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305Phase 191 sites๐Ÿ“ Duarte๐Ÿ“ Newport Beach๐Ÿ“ Orange AstraZeneca ยท Tests: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site๐Ÿ“ Guangzhou Avistone Biotechnology Co., Ltd. ยท Tests: PLB1004 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B395, xT CDx with HLA-LOH assay
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy